Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Focal segmental glomerulosclerosis in the transplanted kidney

Nada Alachkar, MD
Daniel C Brennan, MD, FACP
Andre A Kaplan, MD
Christopher H Kwoh, MD
Section Editor
Barbara Murphy, MB, BAO, BCh, FRCPI
Deputy Editor
Albert Q Lam, MD


Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of injury in the kidney that may have multiple different etiologies, including genetic diseases, infection, toxins, and obesity, as well as previous injury resulting in hyperfiltration of remaining viable nephrons. (See "Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis", section on 'Classification'.)

Primary idiopathic FSGS, which occurs in the absence of a known etiology, commonly progresses to end-stage renal disease (ESRD). When transplantation is performed, primary idiopathic FSGS may recur in the renal allograft.

An overview of FSGS in the renal allograft is presented in this topic review. The pathogenesis and treatment of FSGS in the native kidney are discussed elsewhere. (See "Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis" and "Treatment of primary focal segmental glomerulosclerosis".)


FSGS in the allograft may be recurrent or de novo. Both recurrent and de novo FSGS may be primary idiopathic or related to known causes, such as infection, toxin exposure, genetic mutation, or obesity. In addition, FSGS may develop as a result of hyperfiltration injury related to loss of functioning kidney parenchyma; this form of FSGS is traditionally called secondary FSGS. In this review, FSGS related to a known cause other than hyperfiltration is referred to as primary non-idiopathic FSGS. FSGS that is without a known cause is called primary idiopathic FSGS. The term secondary FSGS is reserved for FSGS that is due to hyperfiltration injury.


The rate of recurrence of primary idiopathic FSGS is difficult to ascertain since it is often not clear whether the patient had primary idiopathic FSGS or FSGS related to other causes as the initial cause of end-stage renal disease (ESRD). Although the reported FSGS recurrence rate averages approximately 30 percent [1-11], it is likely that some of the patients in these studies had FSGS due to a toxin, viral infection, or hyperfiltration injury that would not be expected to recur in the transplant. Thus, the rate of recurrence among patients with primary idiopathic FSGS may be higher than 30 percent. There is, for example, a subgroup in which the disease recurs in approximately one-half of cases. These patients, who almost certainly have primary idiopathic FSGS, tend to be <20 years of age and to have had a rapid clinical course, with the interval from diagnosis of FSGS to ESRD being less than three years [1,4,12,13].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Apr 07, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.
  2. Cheigh JS, Mouradian J, Susin M, et al. Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course. Kidney Int 1980; 18:358.
  3. Kim EM, Striegel J, Kim Y, et al. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 1994; 45:1440.
  4. Pinto J, Lacerda G, Cameron JS, et al. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981; 32:83.
  5. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2:S258.
  6. Striegel JE, Sibley RK, Fryd DS, Mauer SM. Recurrence of focal segmental sclerosis in children following renal transplantation. Kidney Int Suppl 1986; 19:S44.
  7. Lewis EJ. Recurrent focal sclerosis after renal transplantation. Kidney Int 1982; 22:315.
  8. Abbott KC, Sawyers ES, Oliver JD 3rd, et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001; 37:366.
  9. Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001; 12:394.
  10. Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant 2004; 19:1036.
  11. Ding WY, Koziell A, McCarthy HJ, et al. Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 2014; 25:1342.
  12. Briggs JD, Jones E. Recurrence of glomerulonephritis following renal transplantation. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999; 14:564.
  13. Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232.
  14. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.
  15. Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59:328.
  16. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43:368.
  17. IJpelaar DH, Farris AB, Goemaere N, et al. Fidelity and evolution of recurrent FSGS in renal allografts. J Am Soc Nephrol 2008; 19:2219.
  18. Canaud G, Dion D, Zuber J, et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2010; 25:1321.
  19. Fogo AB. The spectrum of FSGS: does pathology matter? Nephrol Dial Transplant 2010; 25:1034.
  20. Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635.
  21. Dantal J, Baatard R, Hourmant M, et al. Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation 1991; 52:827.
  22. Shimizu A, Higo S, Fujita E, et al. Focal segmental glomerulosclerosis after renal transplantation. Clin Transplant 2011; 25 Suppl 23:6.
  23. Nehus EJ, Goebel JW, Succop PS, Abraham EC. Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk. Transplantation 2013; 96:550.
  24. Conlon PJ, Lynn K, Winn MP, et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. Kidney Int 1999; 56:1863.
  25. Felldin M, Nordén G, Svalander C, Nyberg G. Focal segmental glomerulosclerosis in a kidney transplant population: hereditary and sporadic forms. Transpl Int 1998; 11:16.
  26. Carraro M, Caridi G, Bruschi M, et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13:1946.
  27. Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41:1314.
  28. Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.
  29. Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571.
  30. Jungraithmayr TC, Hofer K, Cochat P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 2011; 22:579.
  31. Schachter ME, Monahan M, Radhakrishnan J, et al. Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression. Clin Nephrol 2010; 74:173.
  32. Fuentes GM, Meseguer CG, Carrion AP, et al. Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol 2010; 25:529.
  33. Pham PT, Pham PC. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol Dial Transplant 2012; 27:2965.
  34. Pascual J, Mezrich JD, Djamali A, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation 2007; 83:1429.
  35. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334:878.
  36. Dall'Amico R, Ghiggeri G, Carraro M, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34:1048.
  37. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330:7.
  38. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23:574.
  39. Sharma M, Sharma R, McCarthy ET, Savin VJ. "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999; 10:552.
  40. Sharma M, Sharma R, Reddy SR, et al. Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 2002; 73:366.
  41. Candiano G, Musante L, Carraro M, et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:143.
  42. Gallon L, Leventhal J, Skaro A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012; 366:1648.
  43. Kachurina N, Chung CF, Benderoff E, et al. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis. Am J Physiol Renal Physiol 2016; 310:F1148.
  44. Leroy S, Guigonis V, Bruckner D, et al. Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant 2009; 9:858.
  45. Bitzan M, Babayeva S, Vasudevan A, et al. TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatr Nephrol 2012; 27:2217.
  46. Srivastava T, Garola RE, Kestila M, et al. Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol 2006; 21:711.
  47. Becker-Cohen R, Bruschi M, Rinat C, et al. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 2007; 7:256.
  48. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.
  49. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128:345.
  50. Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21:1422.
  51. Pollak MR. Kidney disease and African ancestry. Nat Genet 2008; 40:1145.
  52. Babayeva S, Miller M, Zilber Y, et al. Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes. Pediatr Nephrol 2011; 26:1071.
  53. Lee BT, Kumar V, Williams TA, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12:1924.
  54. Meehan SM, Pascual M, Williams WW, et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 1998; 65:1192.
  55. Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis 1999; 33:658.
  56. Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 2013; 368:971.
  57. Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy. Semin Nephrol 2003; 23:209.
  58. Barsoum NR, Bunnapradist S, Mougdil A, et al. Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am J Transplant 2002; 2:425.
  59. Li RM, Branton MH, Tanawattanacharoen S, et al. Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 2002; 13:2320.
  60. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347:488.
  61. Chandra P, Kopp JB. Viruses and collapsing glomerulopathy: a brief critical review. Clin Kidney J 2013; 6:1.
  62. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2:326.
  63. Reeves-Daniel AM, DePalma JA, Bleyer AJ, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11:1025.
  64. El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79:643.
  65. Cheigh JS, Mouradian J, Soliman M, et al. Focal segmental glomerulosclerosis in renal transplants. Am J Kidney Dis 1983; 2:449.
  66. Cosio FG, Frankel WL, Pelletier RP, et al. Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival. Am J Kidney Dis 1999; 34:731.
  67. Baum MA, Ho M, Stablein D, et al. Outcome of renal transplantation in adolescents with focal segmental glomerulosclerosis. Pediatr Transplant 2002; 6:488.
  68. Swaminathan S, Lager DJ, Qian X, et al. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 2006; 21:2607.
  69. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5:1179.
  70. D'Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant 2005; 5:351.
  71. Myslak M, Amer H, Morales P, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006; 6:1660.
  72. Lopez-Hellin J, Cantarell C, Jimeno L, et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant 2013; 13:493.
  73. Audard V, Kamar N, Sahali D, et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int 2012; 25:e62.
  74. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3:85ra46.
  75. Gonzalez E, Ettenger R, Rianthavorn P, et al. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 2011; 15:495.
  76. Alachkar N, Wei C, Arend LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 2013; 96:649.
  77. Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:581.
  78. Boddana P, Webb LH, Unsworth J, et al. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon? Clin Transplant 2011; 25:417.
  79. Laufer J, Ettenger RB, Ho WG, et al. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988; 46:540.
  80. Artero M, Biava C, Amend W, et al. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 1992; 92:375.
  81. Torres VE, Velosa JA, Holley KE, et al. Meclofenamate treatment of recurrent idiopathic nephrotic syndrome with focal segmental glomerulosclerosis after renal transplantation. Mayo Clin Proc 1984; 59:146.
  82. Matalon A, Markowitz GS, Joseph RE, et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001; 56:271.
  83. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952.
  84. Cheong HI, Han HW, Park HW, et al. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15:78.
  85. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.1 Differential diagnosis of chronic graft dysfunction. Nephrol Dial Transplant 2002; 17 Suppl 4:4.
  86. Hariharan S. Recurrent and de novo diseases after renal transplantation. Semin Dial 2000; 13:195.
  87. Canaud G, Zuber J, Sberro R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 2009; 9:1081.
  88. Kershaw DB, Sedman AB, Kelsch RC, Bunchman TE. Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. Clin Transplant 1994; 8:546.
  89. Saleem MA, Ramanan AV, Rees L. Recurrent focal segmental glomerulosclerosis in grafts treated with plasma exchange and increased immunosuppression. Pediatr Nephrol 2000; 14:361.
  90. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994; 23:773.
  91. Siegel NJ, Gaudio KM, Krassner LS, et al. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981; 19:454.
  92. Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988; 113:996.
  93. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987; 62:1102.
  94. Banfi G, Colturi C, Montagnino G, Ponticelli C. The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. Transplantation 1990; 50:594.
  95. Vincenti F, Biava C, Tomlanovitch S, et al. Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation. Transplantation 1989; 47:595.
  96. Salomon R, Gagnadoux MF, Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation 2003; 75:810.
  97. Raafat RH, Kalia A, Travis LB, Diven SC. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 2004; 44:50.
  98. Hanevold CD, Greenbaum LA. Nephrotic syndrome after conversion to alternate day steroids in two children with a history of recurrent FSGS. Pediatr Transplant 2003; 7:395.
  99. Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007; 20:1066.
  100. Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007; 67:250.
  101. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008; 8:222.
  102. Apeland T, Hartmann A. Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation. Nephrol Dial Transplant 2008; 23:2091.
  103. Dello Strologo L, Guzzo I, Laurenzi C, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009; 88:417.
  104. Jhaveri KD, Naber TH, Wang X, et al. Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation. Transplantation 2011; 91:e35.
  105. De Smet E, Rioux JP, Ammann H, et al. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 2009; 24:2938.
  106. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369:2416.
  107. Alachkar N, Carter-Monroe N, Reiser J. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2014; 370:1263.
  108. Garin EH, Reiser J, Cara-Fuentes G, et al. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol 2015; 30:469.
  109. Alkandari O, Nampoory N, Nair P, et al. Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report. Exp Clin Transplant 2016; 14:456.
  110. Delville M, Baye E, Durrbach A, et al. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. J Am Soc Nephrol 2016; 27:2520.
  111. Cibrik DM, Kaplan B, Campbell DA, Meier-Kriesche HU. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant 2003; 3:64.
  112. Niaudet P. Podocin and nephrotic syndrome: implications for the clinician. J Am Soc Nephrol 2004; 15:832.
  113. Hosenpud J, Piering WF, Garancis JC, Kauffman HM. Successful second kidney transplantation in a patient with focal glomerulosclerosis. A case report. Am J Nephrol 1985; 5:299.
  114. Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5:2907.